Introduction {#s1}
============

Bladder cancer is the most common malignancy of the urinary tract, accounting for 80,470 new cases and 17,670 deaths in 2019 alone in the United States ([@B30]). When diagnosed, up to 75% of patients present with non-muscle-invasive bladder cancer (NMIBC), about 20% present with muscle-invasive bladder cancer (MIBC), and 5% would have metastatic disease. Although patients with NMIBC have a relatively good prognosis, the prognosis of regional and distant metastatic disease is poor, with 5-year survival rates of 35% and 5%, respectively ([@B23]). Therefore, investigation of novel biomarkers to stratify patients is important for clinical management ([@B31]).

Cancer immunoediting is a process consisting of immunosurveillance and tumor development ([@B20]). Programmed cell death-1 (PD-1) and its ligand programmed cell death-ligand 1 (PD-L1) have an important role in the regulation of responses of our immune system ([@B7]). PD-L1 is also known as B7-H1, CD274, which is expressed on many cancer cells. PD-L1 expression has shown prognostic value in various tumors including pancreatic cancer ([@B9]), colorectal cancer ([@B29]), and non-small cell lung cancer ([@B17]). Recently, many studies ([@B22]; [@B4]; [@B35]; [@B38]; [@B2]; [@B37]; [@B25]; [@B16]; [@B27]; [@B26]; [@B33]) also investigated the prognostic significance of PD-L1 expression in bladder cancer, but the results remain controversial. Therefore, we collected relevant data and performed a meta-analysis to quantify the prognostic role of PD-L1 and analyze the relationship of PD-L1 and clinicopathological parameters in bladder cancer.

Methods {#s2}
=======

Literature Search {#s2_1}
-----------------

This meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines ([@B21]). The research of PubMed, Embase, Web of Science, and Cochrane Library identified relevant studies published in English. The last search was updated on March 2019. A comprehensive search strategy was performed based on the following terms: "programmed death ligand-1," "PD-L1," "B7-H1," "CD274," "bladder cancer," "bladder neoplasm," "bladder tumor," and "bladder urothelial carcinoma." The references of the included studies were also manually checked to identify relevant publications. Ethical approval was waived because we just collected the data from available publications.

Eligibility Criteria {#s2_2}
--------------------

The inclusion criteria were as follows: 1) patients were histologically diagnosed to have bladder cancer; 2) PD-L1 was detected *via* immunohistochemical staining (IHC); 3) the relationship between PD-L1 and survival of bladder cancer was studied; and 4) references are published in English. Exclusion criteria were as follows: 1) duplicate studies; 2) studies provided incomplete data; and 3) meeting abstracts, case reports, reviews, or animal studies.

Data Extraction and Quality Assessment {#s2_3}
--------------------------------------

Two independent investigators extracted the following information from the eligible studies: first author, publication year, country, detection method, sample size, study design, survival analysis, age, and study period. Any disagreement was resolved by discussion. The quality of the selected articles was assessed according to the Newcastle-Ottawa Scale (NOS) ([@B36]). Total quality score of NOS was ranged from 0 to 9, and studies that scored ≥6 were considered as high-quality studies.

Statistical Analysis {#s2_4}
--------------------

Hazard ratios (HRs) and their 95% confidence intervals (CIs) were searched in the original articles or calculated by methods described by [@B32]. The survival outcomes included overall survival (OS), recurrence-free survival (RFS), cancer-specific survival (CSS), and disease-free survival (DFS). The logHR and standard error (SE) were used to present the survival results. An observed HR \> 1 implied a poorer prognosis in patients with high PD-L1 expression, while HR \< 1 indicated a better prognosis. The relationship between PD-L1 expression and clinicopathological features was evaluated by odds ratios (ORs) and corresponding 95% CIs. Cochran's *Q* test and Higgins *I*-squared statistic (*I* ^2^) were used to measure the heterogeneity of the combined HRs ([@B11]). *I* ^2^ \> 50% and/or *p* \< 0.1 suggested significant heterogeneity in terms of statistics, and a random-effects model was utilized. Alternatively, a fixed-effects model was applied. Begg's test was used to detect potential publication bias ([@B1]). All statistical analyses were conducted by using Stata version 12.0 (Stata Corporation, College Station, TX, USA). A two-sided *p* \< 0.05 was considered statistically significant.

Results {#s3}
=======

Study Selection {#s3_1}
---------------

Initial literature search identified 925 records. After removal of duplicate records, 668 studies remained for further evaluation. Then, 631 recorded were excluded by scanning title and/or abstract. Thirty-seven studies were screened by full-text examination, and 26 studies were excluded for following reasons: 20 studies did not provide sufficient for analysis, 2 studies recruited overlapped patients, 2 studies were reviews, 1 study did not focus on PD-L1, and 1 study did not use IHC method for PD-L1 detection. Ultimately, 11 studies ([@B22]; [@B4]; [@B35]; [@B38]; [@B2]; [@B37]; [@B25]; [@B16]; [@B27]; [@B26]; [@B33]) were included in this meta-analysis. The flow diagram is shown in [**Figure 1**](#f1){ref-type="fig"}.

![Flowchart for selection of studies.](fphar-10-00962-g001){#f1}

Study Characteristics {#s3_2}
---------------------

The main characteristics of eligible articles are listed in [**Table 1**](#T1){ref-type="table"}. The studies were published from 2007 to 2019. Three studies ([@B35]; [@B16]; [@B33]) were conducted in China, three were performed in United States ([@B4]; [@B38]; [@B2]), two were in Japan ([@B22]; [@B25]), and one each in Taiwan ([@B37]), Austria ([@B27]) and Egypt ([@B26]). The total sample size was 1,697, ranging from 50 to 318. All studies were a retrospective study design. Regarding clinical outcomes, eight studies reported clinicopathological factors ([@B4]; [@B35]; [@B38]; [@B2]; [@B37]; [@B16]; [@B26]; [@B33]), eight studies reported OS ([@B22]; [@B4]; [@B35]; [@B38]; [@B2]; [@B37]; [@B16]; [@B33]), five studies described RFS ([@B22]; [@B38]; [@B27]; [@B26]; [@B33]), five studies reported CSS ([@B22]; [@B4]; [@B38]; [@B25]; [@B26]), and three studies presented DFS ([@B4]; [@B37]; [@B25]). Furthermore, all studies were with NOS score ≥ 6, indicating that the studies were of high quality.

###### 

Basic characteristics of included studies.

  Author      Year   Country/region   Study design    Duration     No. of patients   Sex (M/F)   Age             Survival analysis   Detection method   NOS score
  ----------- ------ ---------------- --------------- ------------ ----------------- ----------- --------------- ------------------- ------------------ -----------
  Nakanishi   2007   Japan            Retrospective   1996--2005   65                47/18       NA              OS, CSS, RFS        IHC                6
  Boorjian    2008   USA              Retrospective   1990--1994   318               259/59      69 (37--90)     OS, CSS, DFS        IHC                7
  Wang        2009   China            Retrospective   2000--2002   50                40/10       61.7 (42--78)   OS                  IHC                7
  Xylinas     2014   USA              Retrospective   1988--2003   302               244/58      65.9            OS, CSS, RFS        IHC                8
  Bellmunt    2015   USA              Retrospective   NA           160               NA          NA              OS                  IHC                6
  Wu          2016   Taiwan           Retrospective   NA           120               NA          NA              OS, DFS             IHC                6
  Noro        2017   Japan            Retrospective   2004--2014   102               82/20       60 (43--84)     CSS, DFS            IHC                8
  Li          2018   China            Retrospective   2009--2011   98                76/22       NA              OS                  IHC                7
  Pichler     2018   Austria          Retrospective   2006--2015   83                62/21       69 (36--87)     RFS                 IHC                8
  Owyong      2019   Egypt            Retrospective   1997--2004   151               98/53       52 (36--74)     CSS, RFS            IHC                8
  Wang        2019   China            Retrospective   2006--2012   248               214/34      63 (14--94)     OS, RFS             IHC                7

NA, not available; OS, overall survival; CSS, cancer-specific survival; DFS, disease-free survival; RFS, recurrence-free survival; IHC, immunohistochemical staining; NOS, Newcastle-Ottawa Scale.

Impact of PD-L1 on OS, RFS, CSS, and DFS {#s3_3}
----------------------------------------

Eight studies ([@B22]; [@B4]; [@B35]; [@B38]; [@B2]; [@B37]; [@B16]; [@B33]) reported data on PD-L1 and OS in bladder cancer. As shown in [**Figure 2**](#f2){ref-type="fig"} and [**Table 2**](#T2){ref-type="table"}, high PD-L1 was associated with poorer OS (HR = 1.83, 95% CI = 1.24--2.71, *p* = 0.002). Because of significant heterogeneity (*I* ^2^ = 62%, *p* = 0.01), a random-effects model was applied. Five studies ([@B4]; [@B38]; [@B27]; [@B26]; [@B33]) showed the relationship between PD-L1 and RFS. The pooled results were HR = 1.43, 95% CI = 0.89--2.29, *p* = 0.134, with significant heterogeneity (*I* ^2^ = 69.6%, *p* = 0.011) ([**Table 2**](#T2){ref-type="table"}, [**Figure 2**](#f2){ref-type="fig"}). The pooled data from five studies ([@B22]; [@B4]; [@B38]; [@B25]; [@B26]) suggested nonsignificant association between PD-L1 and CSS in bladder cancer (HR = 1.51, 95% CI = 0.80--2.87, *p* = 0.203; *I* ^2^ = 73.8%, *p* = 0.004, [**Table 2**](#T2){ref-type="table"}, [**Figure 2**](#f2){ref-type="fig"}). Moreover, three studies reported the correlation of PD-L1 and DFS ([@B4]; [@B37]; [@B25]). The random-effects model was applied because there was significant heterogeneity (*I* ^2^ = 63.3%, *p* = 0.066) across the studies. The pooled HR and 95%CI were HR = 1.53, 95% CI = 0.88--2.65, *p* = 0.013 ([**Table 2**](#T2){ref-type="table"}, [**Figure 2**](#f2){ref-type="fig"}), suggesting PD-L1 was not correlated to worse DFS.

![Forest plots describing the association between PD-L1 expression and **(A)** OS, **(B)** RFS, **(C)** CSS, and **(D)** DFS of patients with bladder cancer.](fphar-10-00962-g002){#f2}

###### 

Meta-analysis of PD-L1 and prognosis in bladder cancer.

  Survival analysis   No. of studies   No. of patients   Effects model   HR (95% CI)         p       Heterogeneity   
  ------------------- ---------------- ----------------- --------------- ------------------- ------- --------------- -------
  OS                  8                1,361             Random          1.83 (1.24--2.71)   0.002   62              0.01
  RFS                 5                849               Random          1.43 (0.89--2.29)   0.134   69.6            0.011
  CSS                 5                938               Random          1.51 (0.80--2.87)   0.203   73.8            0.004
  DFS                 3                540               Random          1.53 (0.88--2.65)   0.13    63.3            0.066

PD-L1 and Clinicopathological Features {#s3_4}
--------------------------------------

Eight studies ([@B4]; [@B35]; [@B38]; [@B2]; [@B37]; [@B16]; [@B26]; [@B33]) explored the association between PD-L1 and clinicopathological characteristics. The pooled data demonstrated that high PD-L1 was significantly correlated with higher tumor stage (OR = 3.9, 95% CI = 2.71--5.61, *p* \< 0.001) and distant metastasis (OR = 2.5, 95% CI = 1.22--5.1, *p* = 0.012). However, PD-L1 overexpression was not correlated with other clinicopathological factors including sex (OR = 0.88, 95% CI = 0.65--1.21, *p* = 0.433), tumor grade (OR = 1.19, 95% CI = 0.46--3.09, *p* = 0.72), lymph node status (OR = 1.16, 95% CI = 0.63--2.15, *p* = 0.631), and multifocality (OR = 0.77, 95% CI = 0.5--1.18, *p* = 0.226). The correlation between PD-L1 and clinicopathological parameters is presented in [**Table 3**](#T3){ref-type="table"}.

###### 

Association of PD-L1 and clinical factors in bladder cancer.

  Clinical factors                           No. of studies   No. of patients   Effects model   OR (95% CI)         p          Heterogeneity   
  ------------------------------------------ ---------------- ----------------- --------------- ------------------- ---------- --------------- ---------
  Tumor stage (T2--T4 vs Ta--T1)             8                1,447             Fixed           3.9 (2.71--5.61)    \< 0.001   0               0.733
  Sex (male vs female)                       7                1,287             Fixed           0.88 (0.65--1.21)   0.433      13.8            0.325
  Tumor grade (high vs low)                  6                969               Random          1.19 (0.46--3.09)   0.72       86.5            \<0.001
  Lymph node status (positive vs negative)   5                1,139             Random          1.16 (0.63--2.15)   0.631      71.7            0.001
  Multifocality (multifocal vs unifocal)     4                799               Fixed           0.77 (0.5--1.18)    0.226      0               0.659
  Metastasis status (M1 vs M0)               3                466               Fixed           2.5 (1.22--5.1)     0.012      0               0.842

Publication Bias {#s3_5}
----------------

The assessment of the publication bias was carried out by using Begg's funnel plot test. Begg's *p* values for OS, RFS, CSS, and DFS were 0.063, 0.086, 0.221, and 0.602, respectively. Begg's funnel plot was found to be symmetrical ([**Figure 3**](#f3){ref-type="fig"}), indicating no significant publication bias in this meta-analysis.

![Begg's funnel plot for publication bias test including PD-L1 expression and **(A)** OS, **(B)** RFS, **(C)** CSS, and **(D)** DFS in bladder cancer patients.](fphar-10-00962-g003){#f3}

Discussion {#s4}
==========

In the present study, we collected information from 11 recent studies with 1,697 patients and combined the data. The results showed that elevated PD-L1 expression was associated with poorer OS. In addition, PD-L1 overexpression was also connected with higher tumor stage and distant metastasis. There was no obvious evidence of publication bias. The results suggested that PD-L1 expression may be associated with tumor progression and metastasis and could be used as a potential prognostic biomarker. To the best of our knowledge, this is the first pointed meta-analysis investigating the prognostic value of PD-L1 in patients with bladder cancer.

PD-1 and its ligands, PD-L1 and PD-L2, overexpressed in the tumor microenvironment ([@B28]). The interaction of PD-1/PD-L1 can inhibit T-cell activation and proliferation, cytokine production, and cytolytic function ([@B28]). In addition, PD-L1 can also stimulate IL-10 production in T cells to mediate immune suppression ([@B6]). PD-L1 was found to be overexpressed in multiple solid tumor types to generate an immunosuppressive tumor microenvironment ([@B13]; [@B3]; [@B34]). In the present study, we found the association of PD-L1 and higher tumor stage and distant metastasis, which implied the role of PD-L1 in tumor development. A recent study showed that PD-L1 played a critical role in promoting epithelial-to-mesenchymal transition (EMT) phenotype of esophageal cancer ([@B5]). Another study also suggested that PD-L1 expression was a significant risk factor for nodal metastasis in cutaneous squamous cell carcinoma ([@B10]). The activation of IL-6/STAT3/PD-L1 pathway was found to be involved in the EMT process in bladder cancer ([@B40]).

A number of previous studies also reported the prognostic significance of PD-L1 in various cancers. A recent meta-analysis including 2,005 patients showed that high PD-L1 expression was associated with a poor prognosis (HR = 2.04, 95% CI = 1.18--3.54, *p* = 0.01) in non-Hodgkin lymphoma ([@B41]). Li's study showed that PD-L1 overexpression could foresee worse OS and DFS in hepatocellular carcinoma ([@B15]). In addition, another meta-analysis comprising a total of nine studies with 993 patients demonstrated that elevated PD-L1 expression was related with poor OS (HR = 1.63, 95% CI = 1.34--1.98, *p* \< .001) and CSS (HR = 1.86, 95% CI = 1.34--2.57, *p* \< .001) in pancreatic cancer ([@B12]). High PD-L1 expression was also correlated with poor OS in breast cancer ([@B39]). The results of our study were in line with previous studies, suggesting the prognostic value of PD-L1 in bladder cancer. Furthermore, we also found the connection between PD-L1 and distant metastasis in bladder cancer, which may be explained by the role of PD-L1 in EMT process ([@B40]). Recently, many studies also reported the effectiveness and patient-reported outcomes in clinical trials of PD-L1 inhibitors. Madore et al. showed that PD-L1 expression in melanoma showed marked heterogeneity within and between patients, which supported the therapeutic strategies of melanoma patients in a PD-L1-based manner ([@B19]). In addition, stage III melanoma patients with negative PD-L1 expression is associated with worse survival and immune response ([@B18]). A recent meta-analysis demonstrated that PD-L1 expression was significantly associated with mortality and clinical response to anti-PD-1/PD-L1 antibodies in metastatic melanoma patients ([@B8]). The health-related quality of life was also better in advanced cancer patients receiving PD-1/PD-L1 inhibitors than in those receiving standard-of-care therapy ([@B24]). Those studies suggest that the clinical management of PD-1/PD-L1 inhibitors is complex and should be adjusted in the individual patient level.

Notably, age is also a risk factor for bladder cancer patients. In the included studies, five studies ([@B38]; [@B37]; [@B16]; [@B26]; [@B33]) provided the data on age in PD-L1 (+) and PD-L1 (−) groups. However, three studies ([@B38]; [@B37]; [@B26]) presented age in the format of median (range). One study ([@B16]) reported the number of patients in PD-L1 (+) and PD-L1 (−) groups using 65 years as threshold. One study used 60 years ([@B33]) to divide patients. Therefore, the quantitative analysis of PD-L1 expression and age could not be performed because of different cutoff values of age (65 and 60 years). In spite of this, we can find that patients with PD-L1 (+) expression are older than patients with PD-L1 (−) expression in four studies ([@B38]; [@B37]; [@B16]; [@B33]). All five studies ([@B38]; [@B37]; [@B16]; [@B26]; [@B33]) reported nonsignificant association between age and PD-L1 expression (all *p* \> 0.05). Moreover, in the analysis of association between PD-L1 expression and clinical factors, heterogeneity was found on sex, tumor grade, and lymph node status ([**Table 3**](#T3){ref-type="table"}). Because different studies may select patients with various criteria, the heterogeneity among studies may be inherent and may exist. In this occasion, we applied different effects model according to different heterogeneity.

Some limitations need to be mentioned in this meta-analysis. First, the determination of high expression of PD-L1 might vary in the studies because of different cutoff values, which may introduce potential bias. Second, the sample size was relatively small. Only 11 studies with 1,697 patients were included for analysis. For example, for CSS and DFS analysis, only five and three studies were included; the small study may compromise the credibility of the results. Third, although we did not find publication bias in the meta-analysis, the publication bias and selection bias could possibly exist. As we know, studies with significant results are inclined to be published ([@B14]). Therefore, the results should be treated with caution.

Conclusion {#s5}
==========

In summary, the findings of this meta-analysis suggest that elevated PD-L1 expression is associated with poor survival, higher tumor stage, and distant metastasis in bladder cancer. PD-L1 may be useful in the future as a novel prognostic factor in bladder cancer. Nevertheless, due to some limitations, well-designed, multicenter randomized controlled trials should be performed.
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